US/UK/Canada

Share

Contacts

  • Ulf Hannelius

    CEO


    Box 7349, SE-103 90 Stockholm
    +46 8 661 00 26
    +46 8 661 63 68
    https://www.diamyd.com

    • Links

    Quotes

    The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.
    Ulf Hannelius, CEO
    Our top strategic priority is to prepare for a marketing application for Diamyd®
    Ulf Hannelius, CEO
    Pick a time period -
    Tags ( Active)

    First patient included in US Diamyd® and GABA diabetes study

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that the first patient has been randomized and dosed in a pioneering study combining the diabetes vaccine Diamyd® with GABA in children with new onset type 1 diabetes. The aim of the combination therapy is to preserve the body’s residual capacity to produce insulin.The first patient has now received the first injection of either the diabetes vaccine Diamyd® or placebo in the recently FDA approved researcher-initiated GABA and Diamyd® combination study. The study is led by Dr Kenneth McCormick, Professor of Pediatrics at

    First patient enrolled in new study where the Diamyd® diabetes vaccine is administered directly into lymph nodes - DIAGNODE has started

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that the first patient has been enrolled in the DIAGNODE study. In the study a new way to administer the Diamyd® diabetes vaccine is tested, directly into inguinal lymph nodes.DIAGNODE is the first study of its kind, where a low dose of Diamyd® is administered directly into lymph nodes in combination with treatment with vitamin D. The concept, for which Diamyd Medical has submitted a patent application, can be compared to the development in allergy therapy, where the administration of allergen into lymph nodes has

    New analyses by international diabetes expertise provides strong support for the Diamyd® diabetes vaccine

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that internationally leading researchers within the field of type 1 diabetes, independently of Diamyd Medical, has reanalyzed results from previous clinical studies with the Diamyd® diabetes vaccine using alternative statistical methods, termed Bayesian analysis. In an abstract submitted to a scientific meeting the authors conclude that the GAD-based diabetes vaccine Diamyd®, with very high probability preserves patients’ insulin producing capacity and that the continued development should aim to increase the efficacy.The

    Study with Diamyd Medical’s diabetes vaccine awarded EU-funding

    Diamyd Medical (NASDAQ OMX First North, Ticker: DMYD B) informs that the ongoing combination study DIABGAD has been awarded EUR 120 000, corresponding to about SEK 1.1 million, in EU-funding. The grant comes from an FP7 project where Linköping University and Diamyd Medical are included. The DIABGAD study aims to evaluate whether vitamin D and ibuprofen act synergistically with the diabetes vaccine Diamyd® in order to preserve the insulin producing capacity in children newly diagnosed with type 1 diabetes. The first results from the study are expected to be presented in the beginning of 2015.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media